Longitudinal analysis
To assess the effect of lenvatinib starting dose on EQ‐5D and FACT‐G outcomes, mixed models with random coefficients were fitted using the change from baseline for each HRQoL score as the response variable. The least squares (LS) mean change from baseline for each treatment arm was estimated at each timepoint (not including the off‐treatment assessment), along with an overall LS mean. The difference in LS mean for the lenvatinib 18 mg arm versus the 24 mg arm, along with associated 95% CI and 